Roche is taking on 500 new employees and is expanding its production capacity. The Swiss drug maker announced Monday that it was investing a total of $800 million across four locations over the next five years.

The company said in a statement that the expansions in Penzburg, Germany; Basel, Switzerland; and Vacaville and Oceanside, CA, are part of an efforts to support demand for biologics, such as Perjeta, as well as the antibody drug conjugate Kadcyla.

This may sound familiar: AstraZeneca announced Tuesday that, it, too was diving deeper into antibody drug conjugates through an acquisition and by purchasing an equity stake in an ADC-focused company.